Lalazar A, Mahley R W
Gladstone Foundation Laboratories for Cardiovascular Disease, Department of Pathology, University of California, San Francisco 94140-0608.
J Biol Chem. 1989 May 25;264(15):8447-50.
The amino-terminal thrombolytic fragment (residues 1-191) of human apolipoprotein (apo) E was previously shown to be fully active in binding to the low density lipoprotein receptor. In this study, truncated apoE variants with progressive deletions at the carboxyl terminus were produced in Escherichia coli by linker-insertion mutagenesis to define the minimum amino-terminal structure necessary for full receptor binding. These truncated forms of apoE, comprising residues 1-166, 1-170, 1-174, or 1-183, were combined with the phospholipid dimyristoylphosphatidylcholine and tested for their ability to bind to low density lipoprotein receptors on human fibroblasts. All of the truncated variants formed typical discoidal particles when combined with the phospholipid, and the particles could be isolated by density gradient ultracentrifugation. The 1-166 and 1-170 variants had very little receptor binding activity (1%), whereas the 1-183 variant had nearly full activity (85%). The 1-174 variant had 19% activity. We conclude that the 171-183 region of apoE is important for receptor binding, either by contributing one or more residues essential for receptor binding or, more likely, by stabilizing or aligning the region known to be crucial for receptor binding, in the vicinity of residues 140-160.
人载脂蛋白(apo)E的氨基末端溶栓片段(第1 - 191位氨基酸残基)先前已证明在与低密度脂蛋白受体结合方面具有完全活性。在本研究中,通过接头插入诱变在大肠杆菌中产生了羧基末端逐渐缺失的截短型apoE变体,以确定与受体完全结合所需的最小氨基末端结构。这些截短形式的apoE,包含第1 - 166、1 - 170、1 - 174或1 - 183位氨基酸残基,与磷脂二肉豆蔻酰磷脂酰胆碱结合,并测试它们与人成纤维细胞上低密度脂蛋白受体结合的能力。所有截短变体与磷脂结合时均形成典型的盘状颗粒,并且这些颗粒可通过密度梯度超速离心分离。1 - 166和1 - 170变体几乎没有受体结合活性(1%),而1 - 183变体具有近乎完全的活性(85%)。1 - 174变体具有19%的活性。我们得出结论,apoE的171 - 183区域对于受体结合很重要,要么是通过提供一个或多个受体结合所必需的残基,要么更可能是通过在第140 - 160位残基附近稳定或排列已知对受体结合至关重要的区域。